{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/quidelortho-qdel/",
 "dataUrl": "https://clearank.com/stock/quidelortho-qdel/data.json",
 "title": "QDEL Stock Forecast & Price Target (2026)",
 "description": "Is QuidelOrtho (QDEL) a Buy or Sell after its guidance cut? Get the AI trade setup, key support levels and risk analysis. Updated daily.",
 "headline": "QuidelOrtho Corporation (QDEL)",
 "published": "2026-08-09T09:18:38+00:00",
 "modified": "2026-09-27T13:58:55.867+00:00",
 "generated": "2026-09-27T15:56:23.256Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "QDEL",
  "name": "QuidelOrtho Corporation",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Devices",
  "country": "United States",
  "website": "https://www.quidelortho.com"
 },
 "quote": {
  "price": 10.94,
  "previousClose": 10.69,
  "change": 0.25,
  "changePercent": 2.34,
  "open": 10.69,
  "high": 10.95,
  "low": 10.42,
  "volume": 1379800,
  "averageVolume": 1812120,
  "marketCap": 750215171,
  "fiftyTwoWeekHigh": 35.58,
  "fiftyTwoWeekLow": 9.92,
  "marketOpen": false,
  "asOf": "2026-09-27T13:58:55.000Z"
 },
 "statistics": {
  "pe": -0.6560814744916199,
  "eps": -15.43,
  "dividendYield": 0,
  "beta": 0.676,
  "priceToSales": 0.28053814,
  "priceToBook": 0.4209797,
  "revenueTtm": 2674200064,
  "grossMargin": 0.43255666508162943,
  "returnOnEquity": -0.45905998
 },
 "technicals": {
  "rsi": 23.83,
  "macd": -1.08,
  "sma50": 14.21,
  "sma200": 18.43,
  "rsiSignal": "Oversold",
  "trend": "Bearish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Sell",
  "score": 21,
  "consensus": "Sell",
  "fairValue": 10.56,
  "analystTarget": 12,
  "analystCount": 3,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-27T13:58:55.000Z",
  "priceAtAnalysis": 10.94,
  "volatility": {
   "daily": 3.64,
   "risk": "volatile"
  }
 },
 "tradePlan": {
  "bias": "Bearish",
  "conservativeEntry": 11.16,
  "aggressiveEntry": 10.94,
  "stopLoss": 12.1,
  "stopLossPercent": 8.39,
  "targets": [
   10.6,
   10.04,
   9.48
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 5.71,
    "base": 10.84,
    "upside90th": 20.58
   },
   {
    "year": 2028,
    "downside10th": 4.34,
    "base": 10.75,
    "upside90th": 26.6
   },
   {
    "year": 2029,
    "downside10th": 3.51,
    "base": 10.65,
    "upside90th": 32.32
   },
   {
    "year": 2030,
    "downside10th": 2.93,
    "base": 10.56,
    "upside90th": 38.03
   },
   {
    "year": 2031,
    "downside10th": 2.5,
    "base": 10.46,
    "upside90th": 43.85
   },
   {
    "year": 2032,
    "downside10th": 2.16,
    "base": 10.37,
    "upside90th": 49.83
   },
   {
    "year": 2033,
    "downside10th": 1.89,
    "base": 10.28,
    "upside90th": 56.01
   },
   {
    "year": 2034,
    "downside10th": 1.66,
    "base": 10.19,
    "upside90th": 62.4
   },
   {
    "year": 2035,
    "downside10th": 1.48,
    "base": 10.1,
    "upside90th": 69.04
   },
   {
    "year": 2036,
    "downside10th": 1.32,
    "base": 10.01,
    "upside90th": 75.92
   }
  ]
 },
 "faqCount": 8,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "QDEL Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$10.69",
    "Day Range": "$10.42 to $10.95",
    "Prev Close": "$10.69",
    "Volume": "1.38M",
    "52-Week Range": "$9.92 to $35.58",
    "Market Cap": "$750.22M"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis On price-to-sales, the yardstick used here in place of P/E, QDEL trades at 0.2805x, far below the sector average of 3.70x."
   ]
  },
  {
   "id": "financials",
   "title": "QDEL Financial Performance",
   "text": [
    "Analysis: In the last 1 quarters, QDEL beat estimates 1 times. However, the stock fell 1 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "QDEL Analysis",
   "text": [
    "Volume behavior for QuidelOrtho Corporation has been below average, with the latest volume at 1.38 million compared to a 1.81 million average, a decrease of 23.9%. The stock is trading below its 50-day SMA ($14.21) and 200-day SMA ($18.43), and its 20-day EMA ($11.93), reinforcing a bearish trend. The Relative Strength Index (RSI) is at 23.83, indicating an oversold condition, which could suggest a potential short-term bounce, but the MACD at -1.08 points to bearish momentum. Key support levels are not clearly defined given the downward trend, but the current price of $10.94 is approaching the lower end of its recent trading range. Resistance is expected around the 20-day EMA at $11.93 and then the 50-day SMA at $14.21. The oversold RSI suggests a possibility of a reversal, but the persistent trading below key moving averages and below-average volume do not yet support a bullish outlook.",
    "Insiders have purchased $1.2 million worth of stock against $112,000 in sales, indicating moderate confidence in the company's future prospects.",
    "The company reported an EPS of $0.13 for the quarter to June 2026, significantly exceeding the estimated -0.05, a 360% surprise.",
    "The company continues to report negative EPS (-15.43) and profit margins (-39.20%), with forward revenue estimates indicating a continued contraction.",
    "QuidelOrtho Corporation is trading below its 50-day and 200-day moving averages ($14.21 and $18.43), signaling a sustained bearish trend.",
    "The base case scenario for QuidelOrtho Corporation anticipates continued price pressure in the near term, with potential downside towards its long-range projection of $2.93 by 2030, given the current bearish technicals and negative financial trajectory. The median analyst target price of $12.00 suggests limited upside from the current $10.94, reflecting Wall Street's cautious 'Hold' rating. Upside potential could emerge if the company demonstrates a clear path to profitability and revenue growth, potentially driven by new product cycles or market share gains. Conversely, failure to improve earnings, coupled with its high debt load, could accelerate a decline towards the lower end of the long-range projection. The recent insider buying, while positive, needs to be validated by improving operational performance to shift the overall outlook."
   ],
   "lists": {
    "ProTips": [
     "Insider buying of $1.2 million suggests some confidence, but monitor upcoming earnings for signs of operational improvement to validate this signal.",
     "The stock is oversold (RSI 23.83), which may precede a short-term bounce, but the trend remains bearish as it trades below key moving averages.",
     "Given the negative EPS and high debt-to-equity ratio, investors should exercise caution and consider a tight stop-loss strategy if entering a long position."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Insider Net Buying Activity",
     "text": "Insiders have purchased $1.2 million worth of stock against $112,000 in sales, indicating moderate confidence in the company's future prospects.",
     "source": "Insider Trading Data"
    },
    {
     "type": "Bullish",
     "title": "Significant EPS Beat in Recent Quarter",
     "text": "The company reported an EPS of $0.13 for the quarter to June 2026, significantly exceeding the estimated -0.05, a 360% surprise.",
     "source": "Earnings Report"
    },
    {
     "type": "Bearish",
     "title": "Negative Profitability and Declining Revenue",
     "text": "The company continues to report negative EPS (-15.43) and profit margins (-39.20%), with forward revenue estimates indicating a continued contraction.",
     "source": "Financial Analysis"
    },
    {
     "type": "Bearish",
     "title": "Bearish Technical Trend",
     "text": "QuidelOrtho Corporation is trading below its 50-day and 200-day moving averages ($14.21 and $18.43), signaling a sustained bearish trend.",
     "source": "Technical Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "QuidelOrtho Corporation's valuation is currently obscured by negative earnings, with a reported EPS of -15.43 and a negative profit margin of -39.20%. This makes traditional P/E ratio analysis impossible, but the price-to-sales ratio stands at a low 0.28, significantly below the Healthcare sector median of 3.70. The company's debt-to-equity ratio is 1.73, which is higher than the sector average of 1.73, indicating a substantial reliance on debt financing. Despite the negative profitability, the company's revenue growth has been slightly positive at 2.8%, though forward estimates suggest a decline. Return on equity is significantly negative at -45.91%. The low price-to-sales ratio, combined with insider buying activity, might suggest a potential value act for investors willing to overlook current profitability challenges and focus on a turnaround, but the high debt levels and negative margins present significant risks.",
    "QuidelOrtho Corporation's recent earnings performance has been mixed, with a notable EPS beat in the quarter ending June 2026, reporting $0.13 actual versus an estimated -0.05, a 360% surprise. However, this positive surprise was met with a significant price decline of -24.69%. Prior quarters also show volatility, including a substantial EPS miss in the quarter to March 2026 (-0.04 actual vs. 0.36 estimate). Forward revenue estimates indicate a continued contraction, with the current quarter projected to see a -10.00% year-over-year decline.",
    "The primary risk for QuidelOrtho Corporation is its persistent negative profitability, evidenced by a -39.20% net profit margin and a -15.43 EPS, which raises concerns about long-term viability. Additionally, the company is trading significantly below its key moving averages, with the RSI in oversold territory, suggesting potential for further downside pressure. The high debt-to-equity ratio of 1.73 also presents a financial risk, especially if revenue continues to decline and interest expenses increase."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "750.22M"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "N/A (Negative EPS)"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "-15.43"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "35.58"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "9.92"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Oversold SMA Cross Bearish Price vs SMA Bearish MACD Bearish Moving averages show a lagging Death Cross (50-day: $14.21, 200-day: $18.43), price is trading below the 50-day SMA, RSI at 23.8 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Bearish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "23.83"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-1.08"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "14.21"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "18.43"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.36",
    "Correlation with Nasdaq 100 (QQQ)": "+0.32",
    "Correlation with Bitcoin (BTC)": "+0.01",
    "Correlation with Gold (XAU)": "+0.06"
   }
  },
  {
   "id": "trade-plans",
   "title": "QDEL Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for rally",
    "Higher risk, chasing the move",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (23.8) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$10.60",
    "TARGET 2": "$10.04",
    "TARGET 3": "$9.485",
    "STOP LOSS": "$12.10"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+0.82%",
    "Average Feb return": "-7.25%",
    "Average Mar return": "-0.06%",
    "Average Apr return": "-3.26%",
    "Average May return": "+4.28%",
    "Average Jun return": "+6.55%",
    "Average Jul return": "+5.93%",
    "Average Aug return": "-3.34%",
    "Average Sep return": "+4.66%",
    "Average Oct return": "-2.23%",
    "Average Nov return": "+2.33%",
    "Average Dec return": "-0.05%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "3.64%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in QDEL in September 2016 would be worth about $4,948 today, compared with about $35,782 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in QDEL today could grow to about $9,148 by 2036 in the base case, with a bull case near $69,400 and a bear case around $1,206. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "QDEL Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $10.56 for QDEL by 2030 in the base case, from $10.94 today (1.0x over 4 years). The downside path ends near $2.93. These are outcomes of a Monte Carlo simulation run on QDEL's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using QDEL's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "QDEL simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$5.71",
        "$10.84",
        "$20.58"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$4.34",
        "$10.75",
        "$26.60"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$3.51",
        "$10.65",
        "$32.32"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$2.93",
        "$10.56",
        "$38.03"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$2.50",
        "$10.46",
        "$43.85"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$2.16",
        "$10.37",
        "$49.83"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$1.89",
        "$10.28",
        "$56.01"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$1.66",
        "$10.19",
        "$62.40"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$1.48",
        "$10.10",
        "$69.04"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$1.32",
        "$10.01",
        "$75.92"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "WST West Pharmaceutical Services Inc. NYSE $370.44 -0.85%",
     "url": "https://clearank.com/stock/wst-stock-analysis/"
    },
    {
     "text": "FBRX Forte Biosciences, Inc. NASDAQ $76.99 +0.00%",
     "url": "https://clearank.com/stock/fbrx-stock-analysis/"
    },
    {
     "text": "RMD ResMed Inc. NYSE $222.00 +0.05%",
     "url": "https://clearank.com/stock/rmd-stock-analysis/"
    },
    {
     "text": "CVS CVS Health Corporation NYSE $89.13 +4.80%",
     "url": "https://clearank.com/stock/cvs-health-cvs/"
    },
    {
     "text": "ABT Abbott Laboratories NYSE $101.29 +0.22%",
     "url": "https://clearank.com/stock/abbott-laboratories-abt/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $866.64 -0.31%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    },
    {
     "text": "SYK Stryker Corp. NYSE $272.36 +0.97%",
     "url": "https://clearank.com/stock/stryker-syk/"
    },
    {
     "text": "HIMS Hims & Hers Health, Inc. NYSE $29.42 +0.48%",
     "url": "https://clearank.com/stock/hims-hers-health-hims/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "AVGO vs MRVL Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/avgo-vs-mrvl/"
    },
    {
     "text": "ADI vs TXN Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/adi-vs-txn/"
    },
    {
     "text": "General Dynamics (GD) vs Lockheed Martin (LMT) Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/general-dynamics-vs-lockheed-martin/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "QDEL Insider Trading Analysis",
   "facts": {
    "Bought": "$1.2M",
    "Sold": "$112.0K",
    "Insiders": "18",
    "Avg Transaction": "$151.1K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in QDEL",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Nov 21, 2024",
       "cells": [
        "CARLYLE GROUP, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "8.3M",
        "$291.7M"
       ]
      },
      {
       "label": "Jul 25, 2024",
       "cells": [
        "CARLYLE GROUP, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "621.5K",
        "$24.1M"
       ]
      },
      {
       "label": "Aug 2, 2024",
       "cells": [
        "CARLYLE GROUP, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "404.4K",
        "$16.9M"
       ]
      },
      {
       "label": "Jul 31, 2024",
       "cells": [
        "CARLYLE GROUP, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "315.5K",
        "$12.4M"
       ]
      },
      {
       "label": "May 22, 2020",
       "cells": [
        "KROLL WERNER Officer",
        "Sell",
        "68.2K",
        "$11.9M"
       ]
      },
      {
       "label": "Jul 29, 2024",
       "cells": [
        "CARLYLE GROUP, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "262.0K",
        "$10.2M"
       ]
      },
      {
       "label": "Jul 23, 2024",
       "cells": [
        "CARLYLE GROUP, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "234.8K",
        "$8.4M"
       ]
      },
      {
       "label": "Aug 6, 2024",
       "cells": [
        "CARLYLE GROUP, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "205.1K",
        "$8.3M"
       ]
      },
      {
       "label": "Jun 17, 2024",
       "cells": [
        "CARLYLE GROUP, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "227.6K",
        "$8.2M"
       ]
      },
      {
       "label": "Jun 13, 2024",
       "cells": [
        "CARLYLE GROUP, INC. Beneficial Owner of more than 10% of a Class of Security",
        "Sell",
        "208.5K",
        "$8.0M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=QuidelOrtho+Corporation&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is QuidelOrtho Corporation's current stock price and rating?",
   "answer": "QuidelOrtho Corporation (QDEL) is currently trading at $10.94 per share. The consensus rating among analysts is 'Sell', with a consensus score of 21 out of 100."
  },
  {
   "question": "Is QuidelOrtho Corporation stock a buy right now?",
   "answer": "Based on current data, QuidelOrtho Corporation is rated a 'Sell' with a consensus score of 21. The stock is trading below key moving averages and faces challenges with negative earnings and declining revenue, despite some recent insider buying."
  },
  {
   "question": "What are QuidelOrtho Corporation's key technical indicators?",
   "answer": "QuidelOrtho Corporation's technical indicators show the stock is oversold, with an RSI at 23.8. However, it is trading below its 50-day and 200-day moving averages ($14.21 and $18.43), indicating a bearish trend."
  },
  {
   "question": "What is the outlook for QuidelOrtho Corporation's revenue?",
   "answer": "Forward revenue estimates for QuidelOrtho Corporation suggest a continued contraction, with the current quarter projected to experience a -10.00% year-over-year decline and the next quarter a -8.00% decline. The current year is estimated to see a -7.00% revenue decrease."
  },
  {
   "question": "How has QuidelOrtho Corporation performed in recent earnings reports?",
   "answer": "QuidelOrtho Corporation recently reported a significant EPS beat for the quarter to June 2026, but this was accompanied by a sharp stock price decline. Previous earnings have shown inconsistency, including a substantial EPS miss in the quarter to March 2026."
  },
  {
   "question": "What are the main risks facing QuidelOrtho Corporation?",
   "answer": "Key risks include persistent negative profitability, a high debt-to-equity ratio of 1.73, and a bearish technical trend indicated by the stock trading below its major moving averages."
  },
  {
   "question": "What is QDEL stock forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, QuidelOrtho Corporation's stock forecast for 2030 shows a base price of $10.56, with a downside projection of $2.93 and an upside projection of $38.03. These are simulation outcomes, not price targets."
  },
  {
   "question": "What is the Wall Street consensus for QuidelOrtho Corporation?",
   "answer": "The Wall Street consensus for QuidelOrtho Corporation is 'Hold', with a score of 42 out of 100, based on ratings from 3 analysts. The median price target is $12.00, suggesting a 9.7% upside from the current price."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "WST",
    "name": "West Pharmaceutical Services Inc. NYSE",
    "price": "$370.44",
    "change": "-0.85%",
    "url": "https://clearank.com/stock/wst-stock-analysis/"
   },
   {
    "ticker": "FBRX",
    "name": "Forte Biosciences, Inc. NASDAQ",
    "price": "$76.99",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/fbrx-stock-analysis/"
   },
   {
    "ticker": "RMD",
    "name": "ResMed Inc. NYSE",
    "price": "$222.00",
    "change": "+0.05%",
    "url": "https://clearank.com/stock/rmd-stock-analysis/"
   },
   {
    "ticker": "CVS",
    "name": "CVS Health Corporation NYSE",
    "price": "$89.13",
    "change": "+4.80%",
    "url": "https://clearank.com/stock/cvs-health-cvs/"
   },
   {
    "ticker": "ABT",
    "name": "Abbott Laboratories NYSE",
    "price": "$101.29",
    "change": "+0.22%",
    "url": "https://clearank.com/stock/abbott-laboratories-abt/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$866.64",
    "change": "-0.31%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   },
   {
    "ticker": "SYK",
    "name": "Stryker Corp. NYSE",
    "price": "$272.36",
    "change": "+0.97%",
    "url": "https://clearank.com/stock/stryker-syk/"
   },
   {
    "ticker": "HIMS",
    "name": "Hims & Hers Health, Inc. NYSE",
    "price": "$29.42",
    "change": "+0.48%",
    "url": "https://clearank.com/stock/hims-hers-health-hims/"
   }
  ],
  "comparisons": [
   {
    "ticker": "AVGO vs MRVL Comparison",
    "name": "",
    "url": "https://clearank.com/compare/avgo-vs-mrvl/"
   },
   {
    "ticker": "ADI vs TXN Comparison",
    "name": "",
    "url": "https://clearank.com/compare/adi-vs-txn/"
   },
   {
    "ticker": "General Dynamics (GD) vs Lockheed Martin (LMT) Comparison",
    "name": "",
    "url": "https://clearank.com/compare/general-dynamics-vs-lockheed-martin/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "EIS",
    "text": "iShares MSCI Israel ETF",
    "url": "https://clearank.com/etf/eis-etf-analysis/"
   },
   {
    "ticker": "GWRE",
    "text": "Guidewire Software Inc.",
    "url": "https://clearank.com/stock/gwre-stock-analysis/"
   },
   {
    "ticker": "ROST",
    "text": "Ross Stores Inc.",
    "url": "https://clearank.com/stock/rost-stock-analysis/"
   },
   {
    "ticker": "LUGDF",
    "text": "Lundin Gold Inc",
    "url": "https://clearank.com/stock/lugdf-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "TWLO",
    "text": "↓ 7.96%",
    "url": "https://clearank.com/stock/twlo-stock-analysis/"
   },
   {
    "ticker": "CRDO",
    "text": "↑ 7.65%",
    "url": "https://clearank.com/stock/credo-crdo/"
   },
   {
    "ticker": "BLNE",
    "text": "↓ 7.40%",
    "url": "https://clearank.com/stock/blne-beeline-holdings/"
   },
   {
    "ticker": "GRT/USD",
    "text": "↑ 20.82%",
    "url": "https://clearank.com/crypto/the-graph-grt/"
   },
   {
    "ticker": "SEI/USD",
    "text": "↑ 19.29%",
    "url": "https://clearank.com/crypto/sei-sei/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "GEHC",
    "text": "GE HealthCare",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "MDT",
    "text": "Medtronic plc",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   },
   {
    "ticker": "NEOG",
    "text": "Neogen Corporation",
    "url": "https://clearank.com/stock/neogen-neog/"
   },
   {
    "ticker": "OFIX",
    "text": "Orthofix Medical",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "SYK",
    "text": "Stryker Corporation",
    "url": "https://clearank.com/stock/stryker-syk/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/08/qdel-quidelortho.png",
     "url": "https://clearank.com/wp-content/uploads/2026/08/qdel-quidelortho.png",
     "width": "1280",
     "height": "720",
     "caption": "QuidelOrtho Corporation (QDEL) stock price analysis chart for August 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/quidelortho-qdel/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/quidelortho-qdel/",
        "name": "QuidelOrtho Corporation (QDEL) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/quidelortho-qdel/#webpage",
     "url": "https://clearank.com/stock/quidelortho-qdel/",
     "name": "QDEL Stock Forecast & Price Target (2026)",
     "datePublished": "2026-08-09T09:18:38+00:00",
     "dateModified": "2026-09-27T13:58:55+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/08/qdel-quidelortho.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/quidelortho-qdel/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/quidelortho-qdel/#richSnippet",
     "headline": "QDEL Stock Forecast & Price Target (2026)",
     "name": "QDEL Stock Forecast & Price Target (2026)",
     "description": "Is QuidelOrtho (QDEL) a Buy or Sell after its guidance cut? Get the AI trade setup, key support levels and risk analysis. Updated daily.",
     "datePublished": "2026-08-09T09:18:38+00:00",
     "dateModified": "2026-09-27T13:58:55+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "QuidelOrtho Corporation",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "QDEL"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "QuidelOrtho Corporation is a diagnostic healthcare company that develops, manufactures, and markets testing solutions used across the healthcare continuum. The company focuses on in vitro diagnostics, with products and platforms spanning immunoassay, molecular testing, clinical chemistry, point-of-c",
      "tickerSymbol": "QDEL",
      "sameAs": "https://www.quidelortho.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/quidelortho-qdel/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/08/qdel-quidelortho.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/quidelortho-qdel/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is QuidelOrtho Corporation's current stock price and rating?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "QuidelOrtho Corporation (QDEL) is currently trading at $10.94 per share. The consensus rating among analysts is 'Sell', with a consensus score of 21 out of 100."
     }
    },
    {
     "@type": "Question",
     "name": "Is QuidelOrtho Corporation stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on current data, QuidelOrtho Corporation is rated a 'Sell' with a consensus score of 21. The stock is trading below key moving averages and faces challenges with negative earnings and declining revenue, despite some recent insider buying."
     }
    },
    {
     "@type": "Question",
     "name": "What are QuidelOrtho Corporation's key technical indicators?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "QuidelOrtho Corporation's technical indicators show the stock is oversold, with an RSI of 23.83. However, it is trading below its 50-day ($14.21) and 200-day ($18.43) moving averages, indicating a bearish trend."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for QuidelOrtho Corporation's revenue?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Forward revenue estimates for QuidelOrtho Corporation suggest a continued contraction, with the current quarter projected to experience a -10.00% year-over-year decline and the next quarter a -8.00% decline. The current year is estimated to see a -7.00% revenue decrease."
     }
    },
    {
     "@type": "Question",
     "name": "How has QuidelOrtho Corporation performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "QuidelOrtho Corporation recently reported a significant EPS beat for the quarter to June 2026, but this was accompanied by a sharp stock price decline. Previous earnings have shown inconsistency, including a substantial EPS miss in the quarter to March 2026."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing QuidelOrtho Corporation?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks include persistent negative profitability, a high debt-to-equity ratio of 1.73, and a bearish technical trend indicated by the stock trading below its major moving averages."
     }
    },
    {
     "@type": "Question",
     "name": "What is QDEL stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, QuidelOrtho Corporation's stock forecast for 2030 shows a base price of $10.56, with a downside projection of $2.93 and an upside projection of $38.03. These are simulation outcomes, not price targets."
     }
    },
    {
     "@type": "Question",
     "name": "What is the Wall Street consensus for QuidelOrtho Corporation?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The Wall Street consensus for QuidelOrtho Corporation is 'Hold', with a score of 42 out of 100, based on ratings from 3 analysts. The median price target is $12.00, suggesting a 9.7% upside from the current price."
     }
    }
   ]
  }
 ]
}